GlassScriptPhysician profile
Generoso S Nery
NPI 1851408116
$3,820.67
in general payments reported to CMS, 2019-2025
23 companies · $651 in 2025
The $651 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,957 · 2020: $428 · 2021: $124 · 2023: $228 · 2024: $433 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $514.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $396.00 | 2019-2020 | |
| Corcept Therapeutics | $364.54 | 2024-2025 | Korlym |
| Pfizer INC. | $226.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $224.65 | 2019-2020 | |
| Novo Nordisk INC | $196.44 | 2019-2023 | |
| Sanofi Pasteur INC. | $193.88 | 2019-2020 | |
| Astellas Pharma US INC | $154.85 | 2019 | |
| Medicure Pharma INC. | $147.71 | 2023 | Zypitamag |
| Neurocrine Biosciences, INC. | $139.93 | 2025 | |
| Amgen INC. | $129.30 | 2025 | Repatha |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Intra-Sana Laboratories | $124.99 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Biohaven Pharmaceuticals, INC. | $123.65 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $121.82 | 2024 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $121.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $111.41 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $100.62 | 2019 | |
| Dexcom, INC. | $78.12 | 2024 | Dexcom G7 Gss (161) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.01 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $63.40 | 2019 | |
| Allergan, INC. | $58.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $33.46 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Generoso Nery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.